Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
(1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1575 · Cited by 152 · cited 1×
“[85], and TNF-mediated apoptosis of fibroblasts [86].”
RetractedThe IL-15Rα Chain Signals Through Association with Syk in Human B Cells
Bulanova, E., Budagian, V., Pohl, T., Krause, H., Dürkop, H., Paus, R., & Bulfone-Paus, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6292 · Cited by 84 · cited 2×
“and dendritic cells in particular, simultaneously express the IL15Ra chain, which, in contrast to IL-2Ra, binds IL-15 with high affinity (Ka 10 11 M) [43] and can mediate signal transduction [44].”
BackgroundRetractedA promiscuous liaison between IL‐15 receptor and Axl receptor tyrosine kinase in cell death control
Budagian, V., Bulanova, E., Orinska, Z., Thon, L., Mamat, U., Bellosta, P., Basilico, C., Adam, D., Paus, R., & Bulfone‐Paus, S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600874 · Cited by 75 · cited 2×
“On the other hand, both the IL-2/15b chain and a unique IL-15Ra chain signal through SYK protein tyrosine kinase of the SYK/ZAP-70 family [44,69], and IL-15Ra activates protein tyrosine kinase AXL [70].”
BackgroundRetractedBulanova, E., Budagian, V., Duitman, E., Orinska, Z., Krause, H., Rückert, R., Reiling, N., & Bulfone-Paus, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610036200 · Cited by 63 · cited 2×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundRetractedReverse Signaling through Membrane-bound Interleukin-15
Budagian, V., Bulanova, E., Orinska, Z., Pohl, T., Borden, E. C., Silverman, R. H., & Bulfone‐Paus, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403182200 · Cited by 60
RetractedChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundDevelopment of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
“treatments, thus limiting their clinical application as a monotherapy for cancer patients.(172,174,182) Second-generation, IL-2based compounds developed with improved pharmacodynamic properties have displayed promising response rates when combined with ICP therapy.”
BackgroundCytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
“More recently, alternative strategies have been attempted, including intraperitoneal administration of an IL-12 plasmid, tumor injections of an IL-12-expressing adenovirus vector, the combination of IL-12 with a vaccine containing tumor cells fused with DCs, adoptive immunotherapy with IL-12-engineered lymphoid cells,…”
BackgroundMethodInfluentialThe Immunobiology of the Interleukin-12 Family: Room for Discovery
Tait Wojno, E. D., Hunter, C. A., & Stumhofer, J. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.011 · Cited by 482
“These issues are exemplified in the multiple trials that utilized IL-12 as a treatment for different cancers, which revealed significant toxicity and limited efficacy (Lasek et al., 2014).”
BackgroundLocalized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
“The tester dose was found to blunt the toxicity induced by subsequent doses (41).”
BackgroundDooley, K., McConnell, R. E., Xu, K., Lewis, N. D., Haupt, S., Youniss, M. R., Martin, S., Sia, C. L., McCoy, C., Moniz, R. J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.020 · Cited by 307
The role of cytokines in the regulation of NK cells in the tumor environment
Konjević, G. M., Vuletić, A. M., Mirjačić Martinović, K. M., Larsen, A. K., & Jurišić, V. B. (2019) · Cytokine · doi:10.1016/j.cyto.2019.02.001 · Cited by 279
Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 263
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
In vivo gene delivery mediated by non-viral vectors for cancer therapy
Mohammadinejad, R., Dehshahri, A., Sagar Madamsetty, V., Zahmatkeshan, M., Tavakol, S., Makvandi, P., Khorsandi, D., Pardakhty, A., Ashrafizadeh, M., Ghasemipour Afshar, E., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.038 · Cited by 238
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J.-M., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 235
Chen, S., Zhu, H., & Jounaidi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02005-w · Cited by 234
“491 The generation of mouse cytomegalovirus-speci fi c long-lived memory NK cells with higher responses compared to naïve NK cells was shown to be dependent on IL-12-STAT4 signaling.”
BackgroundLi, Y., Su, Z., Zhao, W., Zhang, X., Momin, N., Zhang, C., Wittrup, K. D., Dong, Y., Irvine, D. J., & Weiss, R. (2020) · Nature Cancer · doi:10.1038/s43018-020-0095-6 · Cited by 233
Cytokine-Induced Modulation of Colorectal Cancer
Mager, L. F., Wasmer, M.-H., Rau, T. T., & Krebs, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00096 · Cited by 216
Immunology of IL-12: An update on functional activities and implications for disease
Ullrich, K. A.-M., Schulze, L. L., Paap, E.-M., Müller, T. M., Neurath, M. F., & Zundler, S. (2020) · EXCLI journal · doi:10.17179/excli2020-3104 · Cited by 216
“…innate (NK cells) and adaptive (cytotoxic T lymphocytes) immune system, IL-12 appears to be a promising mediator of anti-tumoral immunotherapy, which has been the subject of many reviews (Tait Wojno et al., 2019; Golab and Zagozdzon, 1999; Lasek et al., 2014; Tugues et al., 2015; Yan et al., 2018).”
BackgroundInfluentialInterleukin-12: Functional activities and implications for disease
Zundler, S., & Neurath, M. F. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.003 · Cited by 212
Cancer immunotherapy beyond immune checkpoint inhibitors
Marin-Acevedo, J. A., Soyano, A. E., Dholaria, B., Knutson, K. L., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0552-6 · Cited by 212
“Cytokine gene therapy IL-12 has been considered a good option for immunotherapy given its potent anti-tumor effect [124].”
BackgroundModular design of synthetic receptors for programmed gene regulation in cell therapies
Zhu, I., Liu, R., Garcia, J. M., Hyrenius-Wittsten, A., Piraner, D. I., Alavi, J., Israni, D. V., Liu, B., Khalil, A. S., & Roybal, K. T. (2022) · Cell · doi:10.1016/j.cell.2022.03.023 · Cited by 202
Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives
Badgeley, A., Anwar, H., Modi, K., Murphy, P., & Lakshmikuttyamma, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188494 · Cited by 196
Nakao, S., Arai, Y., Tasaki, M., Yamashita, M., Murakami, R., Kawase, T., Amino, N., Nakatake, M., Kurosaki, H., Mori, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7992 · Cited by 187
Glassman, C. R., Mathiharan, Y. K., Jude, K. M., Su, L., Panova, O., Lupardus, P. J., Spangler, J. B., Ely, L. K., Thomas, C., Skiniotis, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.018 · Cited by 181
Kueberuwa, G., Kalaitsidou, M., Cheadle, E., Hawkins, R. E., & Gilham, D. E. (2018) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2017.12.003 · Cited by 179
“Together these actions have the potential to exert significant anti-tumor potency, which has been the subject of much investigation.(36,37)”
BackgroundSynthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy
Nissim, L., Wu, M.-R., Pery, E., Binder-Nissim, A., Suzuki, H. I., Stupp, D., Wehrspaun, C., Tabach, Y., Sharp, P. A., & Lu, T. K. (2017) · Cell · doi:10.1016/j.cell.2017.09.049 · Cited by 175
“…Outputs Triggers Effective T Cell-Dependent Tumor Killing Since combination therapy has shown enhanced therapeutic efficacy over monotherapies (Lasek et al., 2014; Mahoney et al., 2015; Tugues et al., 2015) and STE expression alone was insufficient to achieve strong anti-tumor effects in…”
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Rafiq, S., Purdon, T. J., Daniyan, A. F., Koneru, M., Dao, T., Liu, C., Scheinberg, D. A., & Brentjens, R. J. (2017) · Leukemia · doi:10.1038/leu.2016.373 · Cited by 153
Restoring, releasing or replacing adaptive immunity in chronic hepatitis B
Maini, M. K., & Burton, A. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0196-9 · Cited by 168
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 161
Lai, I. K., Swaminathan, S., Baylot, V., Mosley, A. R., Dhanasekaran, R., Gabay, M., & Felsher, D. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0431-x · Cited by 156
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Abdou, Y. G., Goudarzi, A., Yu, J. X., Upadhaya, S., Vincent, B. G., & Carey, L. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00486-y · Cited by 147
Design and application of oncolytic viruses for cancer immunotherapy
Ylösmäki, E., & Cerullo, V. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.11.016 · Cited by 136
“IL-12 is a pleiotropic cytokine activating both innate and adaptive immunity and acting as a major orchestrator of Th1-type immune response against cancer [41].”
BackgroundMittal, D., Vijayan, D., Putz, E. M., Aguilera, A. R., Markey, K. A., Straube, J., Kazakoff, S., Nutt, S. L., Takeda, K., Hill, G. R., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0341 · Cited by 130
“IL12 has antimetastatic function (31, 32) and besides CD103þ DCs, there are other DCs, macrophages, and neutrophils that can potentially contribute to increased IL12 levels.”
BackgroundEmerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 138
Role of chitinase-like proteins in cancer
Kzhyshkowska, J. G., Yin, S., Liu, T., Riabov, V., & Larionova, I. (2016) · Biological Chemistry · doi:10.1515/hsz-2015-0269 · Cited by 137
“However, overall outcome of such regulation is unclear since SI-CLP induced cytokines are known to both facilitate (IL-1β, IL-6, IL-13) and suppress (IL-12) tumor progression (Fujisawa et al., 2012; Voronov et al., 2013; Landskron et al., 2014; Lasek et al., 2014).”
BackgroundEngineering interferons and interleukins for cancer immunotherapy
Holder, P. G., Lim, S. A., Huang, C., Sharma, P. A., Dagdas, Y. S., Bulutoglu, B., & Sockolosky, J. T. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114112 · Cited by 138
Agarwal, Y., Milling, L. E., Chang, J. Y. H., Santollani, L., Sheen, A. M., Lutz, E. A., Tabet, A., Stinson, J. A., Ni, K., Rodrigues, K. A., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00831-9 · Cited by 136
Trial watch: Dendritic cell-based anticancer immunotherapy
Garg, A. D., Vara Perez, M., Schaaf, M., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328341 · Cited by 117
“ligands (which stimulate IL-12 secretion) is generally encouraged.(173,174) It is important to mention that only one cellular”
BackgroundEngineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Pires, I. S., Hammond, P. T., & Irvine, D. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100035 · Cited by 131
IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy
Luo, Y., Chen, Z., Sun, M., Li, B., Pan, F., Ma, A.-Q., Liao, J., Yin, T., Tang, X., Huang, G., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121341 · Cited by 128
Chronic Inflammation’s Transformation to Cancer: A Nanotherapeutic Paradigm
Sohrab, S. S., Raj, R., Nagar, A., Hawthorne, S. J., Paiva‐Santos, A. C., Kamal, M. A., El-Daly, M. M., Azhar, E. I., & Sharma, A. (2023) · Molecules · doi:10.3390/molecules28114413 · Cited by 124
Chiocca, E. A., Gelb, A. B., Chen, C. C., Rao, G., Reardon, D. A., Wen, P. Y., Bi, W. L., Peruzzi, P., Amidei, C., Triggs, D., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab271 · Cited by 119
Behzadi, P., Behzadi, E., & Ranjbar, R. (2016) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.63.2016.1.1 · Cited by 120
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00402 · Cited by 114
“Interleukin 12 Interleukin 12 is another cytokine with well-studied antitumor activity, which is mainly mediated by stimulation of IFN-γ production in cytotoxic cells (CD8 T-cells and NK cells) and Th1 cells (Lasek et al., 2014).”
BackgroundOncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
Nguyen, H.-M., Guz-Montgomery, K., & Saha, D. (2020) · Cells · doi:10.3390/cells9020400 · Cited by 114
“Despite encouraging success in preclinical studies [4], the early stages of IL-12 clinical trials did not meet expectations.”
BackgroundDesigning herpes viruses as oncolytics
Peters, C. W., & Rabkin, S. D. (2015) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2015.10 · Cited by 113
Harnessing cancer immunotherapy during the unexploited immediate perioperative period
Matzner, P., Sandbank, E., Neeman, E., Zmora, O., Gottumukkala, V. N. R., & Ben‐Eliyahu, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0319-9 · Cited by 110
IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines
Jia, Z., Ragoonanan, D. S., Mahadeo, K. M., Gill, J. B., Gorlick, R. G., Shpal, E., & Li, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952231 · Cited by 110
“The most commonly reported hematologic toxicities of recombinant IL-12 (rIL-12) protein therapy are neutropenia and thrombocytopenia (17).”
BackgroundNanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy
Zhuang, J., Holay, M., Park, J. H., Fang, R. H., Zhang, J., & Zhang, L. (2019) · Theranostics · doi:10.7150/thno.37216 · Cited by 107
“However, the direct administration of IL12 can cause severe adverse effects, which undermine its benefits in cancer immunotherapy applications [186].”
BackgroundLewis, N. D., Sia, C. L., Kirwin, K., Haupt, S., Mahimkar, G., Zi, T., Xu, K., Dooley, K., Jang, S. C., Choi, B., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0484 · Cited by 106
Bench to bedside: NK cells and control of metastasis
Krasnova, Y., Putz, E. M., Smyth, M. J., & Souza-Fonseca-Guimarães, F. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.10.001 · Cited by 97
Shan, H., Dou, W., Zhang, Y., & Qi, M. (2020) · Nanoscale · doi:10.1039/d0nr04520a · Cited by 97
Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martinez‐García, M., Rovira, A., Rojo, F., Albanell, J., & López‐Botet, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01544 · Cited by 97
“The authors are supported by coordinated research projects from Fundación Española contra el Cáncer (GCB15152947MELE) and Proyecto Integrado de Excelencia ISCIII (PIE 2015/00008); ML-B and AM are supported by Worldwide Cancer Research Foundation (15-1146); ML-B by Plan Estatal I + D Retos (SAF2013-49063-C2-1-R; SAF201…”
BackgroundZika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 96
“UTR ZIKV to express cytokines or chemokines, for example, IL-6 (87), IL-12 (88, 89), and/or TNF316”
BackgroundImmunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress
Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 97
Advances in immunotherapeutic research for glioma therapy
Miyauchi, J. T., & Tsirka, S. E. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8695-5 · Cited by 94
“The potential for viruses to induce potent immunostimulatory effects has also been explored using modified adenovirus expressing IL12 with activator ligand veledimex to potentiate its effects [42].”
Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy
Siwicki, M., Gort-Freitas, N. A., Messemaker, M., Bill, R., Gungabeesoon, J., Engblom, C., Zilionis, R., Garris, C., Gerhard, G. M., Kohl, A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi7083 · Cited by 88
Saha, D., Martuza, R. L., & Rabkin, S. D. (2018) · Immunotherapy · doi:10.2217/imt-2018-0009 · Cited by 89
Brempelis, K. J., Cowan, C. M., Kreuser, S. A., Labadie, K. P., Prieskorn, B. M., Lieberman, N. A. P., Ene, C., Moyes, K. W., Chinn, H. K., DeGolier, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001356 · Cited by 88
M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
Jarosz–Biej, M., Kamińska, N., Matuszczak, S., Cichoń, T., Pamuła‐Piłat, J., Czapla, J., Smolarczyk, R., Skwarzyńska, D., Kulik, K., & Szala, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191012 · Cited by 89
Cytokine engineering for targeted cancer immunotherapy
Bonati, L., & Tang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.007 · Cited by 85
Jafarzadeh, A., & Nemati, M. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.09.003 · Cited by 84
Pawar, V. K., Singh, Y., Sharma, K., Shrivastav, A., Sharma, A., Singh, A., Meher, J. G., Singh, P. K., Raval, K., Kumar, A., et al. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.09.059 · Cited by 83
Birocchi, F., Cusimano, M., Rossari, F., Beretta, S., Rancoita, P. M. V., Ranghetti, A., Colombo, S., Costa, B., Angel, P. E., Sanvito, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl4106 · Cited by 81
Dendritic-Tumor Fusion Cell-Based Cancer Vaccines
Koido, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060828 · Cited by 81
“The PD1 ligand, PD-L1, in tumor cells is upregulated by IFN-γ produced by activated CTLs.”
BackgroundInfluentialNucleic Acid-Based Approaches for Tumor Therapy
Hager, S., Fittler, F. J., Wagner, E., & Bros, M. (2020) · Cells · doi:10.3390/cells9092061 · Cited by 81
“Another interesting candidate for cancer immunotherapy is IL-12 because of its ability to activate both the innate and the adaptive immune system [351].”
BackgroundJia, W., Wu, Y., Xie, Y., Yu, M., & Chen, Y. (2025) · Advanced Materials · doi:10.1002/adma.202413603 · Cited by 81
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 77
“IL-12 can enhance T cell activity, interferon g (IFNg) production and Th1 polarization, as well as serve as chemoattractant for various immune cells (69).”
BackgroundNew Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
Corraliza-Gorjón, I., Somovilla-Crespo, B., Santamaría, S. S., García‐Sanz, J. A., & Kremer, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01804 · Cited by 74
Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment
Autzen, A. A. A., Gale, E. C., Roth, G. A., Maikawa, C. L., Correa, S., Yu, A. C., & Appel, E. A. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00812 · Cited by 73
Jones, D. S., Nardozzi, J. D., Sackton, K. L., Ahmad, G., Christensen, E., Ringgaard, L., Chang, D.-K., Jæhger, D. E., Konakondla, J. V. V., Wiinberg, M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi8075 · Cited by 72
“The clinical utility of IL-12, however, has been limited by severe toxicities upon systemic administration ( 27 – 29 ).”
BackgroundCytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives
Atallah‐Yunes, S. A., & Robertson, M. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872010 · Cited by 72
Rodríguez, M. M., Fiore, E. J., Bayo, J., Atorrasagasti, C., García, M. G., Onorato, A. M., Domínguez, L. M., Malvicini, M., & Mazzolini, G. D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.012 · Cited by 68
Cai, H., Wang, C., Shukla, S., & Steinmetz, N. F. (2019) · Advanced Science · doi:10.1002/advs.201802281 · Cited by 68
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
Mortezaee, K., & Majidpoor, J. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00667-8 · Cited by 69
Akasaki, Y., Kikuchi, T., Homma, S., Koido, S., Ohkusa, T., Tasaki, T., Hayashi, K., Komita, H., Watanabe, N., Suzuki, Y., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1905-7 · Cited by 67
Dual-target IL-12-containing nanoparticles enhance T cell functions for cancer immunotherapy
Li, J., Lin, W., Chen, H., Xu, Z. P., Ye, Y., & Chen, M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104042 · Cited by 67
Wang, R., Chen, J., Wang, W., Zhao, Z., Wang, H., Liu, S., Li, F., Wan, Y., Yin, J., Wang, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003809 · Cited by 66
Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
Mohammad, G. R. K. S., Ghahremanloo, A., Soltani, A., Fathi, E., & Hashemy, S. I. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29491 · Cited by 66
Immunotherapy for Gastric Cancer: Time for a Personalized Approach?
Dolcetti, R., Re, V. D., & Canzonieri, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061602 · Cited by 65
“Although DC-tumor hybrids are safe and have induced efficient antitumor immune responses in early clinical trials, limited positive clinical responses have been reported in GC, with better results occurring with the use of costimulation with IL-12 [129] and the use of the of combination of TLR2 and TLR4 agonists [130].”
ResultInfluentialCytokines and their role as immunotherapeutics and vaccine Adjuvants: The emerging concepts
Rahman, T., Das, A., Abir, M. H., Nafiz, I. H., Mahmud, A. R., Sarker, M. R., Emran, T. B., & Hassan, M. M. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156268 · Cited by 66
Ahmed, J., Chard, L. S., Yuan, M., Wang, J., Howells, A., Li, Y., Li, H., Zhang, Z., Lu, S., Gao, D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000415 · Cited by 65
Barton, K. N., Siddiqui, F., Pompa, R., Freytag, S. O., Khan, G. N., Dobrosotskaya, I. Y., Ajlouni, M., Zhang, Y., Cheng, J., Movsas, B., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.11.006 · Cited by 64
“Targeted or tumor-specific expression of IL12 appears to provide the benefits of IL12-mediated tumor immunotherapy with less of the toxicity observed with systemic administration.(18) This is the approach we employed by engineering our oncolytic adenovirus that expresses the suicide fusion genes yCD/mutTKSR39 and Ad5-…”
BackgroundInfluentialSun, Y., Liu, L., Zhou, L., Yu, S., Lan, Y., Liang, Q., Liu, J., Cao, A., & Liu, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14405 · Cited by 63
Rossowska, J., Anger, N., Wegierek, K., Szczygieł, A., Mierzejewska, J., Milczarek, M., Szermer-Olearnik, B., & Pajtasz-Piasecka, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00211 · Cited by 61
Interleukin-12 as an in situ cancer vaccine component: a review
Cheng, E. M., Tsarovsky, N. W., Sondel, P. M., & Rakhmilevich, A. L. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03144-1 · Cited by 62
Inflammatory Networks in Renal Cell Carcinoma
Kruk, L., Mamtimin, M., Braun, A., Anders, H., Andrassy, J., Gudermann, T. W., & Mammadova‐Bach, E. (2023) · Cancers · doi:10.3390/cancers15082212 · Cited by 62
El-Shemi, A. G., Ashshi, A. M., Na, Y., Li, Y., Basalamah, M. A., Al-Allaf, F. A., Oh, E., Jung, B., & Yun, C. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0353-8 · Cited by 62
“peri-tumor extracellular matrix and tumor stroma [23].”
BackgroundInfluentialHu, Q., Shang, L., Wang, M., Tu, K., Hu, M. Y., Yu, Y., Xu, M., Kong, L., Guo, Y., & Zhang, Z. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901858 · Cited by 62
Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?
Zhang, Y., & Nagalo, B. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898631 · Cited by 61
Elkhattouti, A., Hassan, M., & Gomez, C. R. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00158 · Cited by 56
Hombach, A. A., Barden, M., Hannappel, L., Chmielewski, M. M., Rappl, G., Sachinidis, A., & Abken, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.011 · Cited by 60
“Tethering IL12 to the CAR, moreover, has the benefit of potentially low toxicity, while systemically delivered IL12 has a very small therapeutic window with the risk of inducing severe cytotoxicity.(39) Although a xenogenic mouse model is of limited value for predicting potential toxicity, our results are in line with…”
ResultHuman fibronectin extra domain B as a biomarker for targeted therapy in cancer
Lieverse, R. I. Y., Marcus, D., van der Wiel, A. M.-M. A., Limbergen, E. J. V., Theys, J., Yaromina, A., Lambin, P., & Dubois, L. J. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12705 · Cited by 59
“The injection of recombinant IL-12 at therapeutic dose levels often initiates substantial toxicities in patients, including anorexia, bone marrow suppression, flu-like symptoms, hepatotoxicity and even death (Lasek et al., 2014; List and Neri, 2013).”
BackgroundClinical implication of cellular vaccine in glioma: current advances and future prospects
Yan, Y., Zeng, S., Gong, Z., & Xu, Z. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01778-6 · Cited by 59
“Accounting for the narrow therapeutic index of rhIL-12 [84], the alteration of chemoresistance-associated peptides may achieve susceptibility of TAA-expressing glioma cells to the specific immune response in DC-based immunotherapy.”
BackgroundCanton, D. A., Shirley, S. A., Wright, J. H., Connolly, R. J., Burkart, C., Mukhopadhyay, A., Twitty, C., Qattan, K. E., Campbell, J. S., Le, M. H., et al. (2017) · Immunotherapy · doi:10.2217/imt-2017-0096 · Cited by 60
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.